[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628042":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":34,"responsibleParty":51,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":18,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":18,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Liaquat National Hospital & Medical College","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","ACTIVE_COMPARATOR","Atropine 0.01% eye drops",[13],"Drug: Atropine 0.01% eye drops",{"label":15,"type":16,"description":17,"interventionNames":18},"Group B","NO_INTERVENTION","No eye drops",null,[20],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":18},"DRUG","Eye drops atropine 0.01% given once nightly to group A for 6 months",[9],[25],{"name":26,"affiliation":27,"role":28},"Hina Nadeem, MBBS","LNHMC","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","03252120568","hinanadeem1508@gmail.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":18,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"LiaquatNHMC","RECRUITING","Karachi","Sindh","Pakistan","PK",{"type":43,"coordinates":44},"Point",[45,46],67.0104,24.8608,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":32,"phoneExt":18,"email":33},"Hina Nadeem",{"type":28,"investigatorFullName":50,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Dr. Hina Nadeem, principal Investigator","100628042","phase-2-the-effect-of-001-atropine-eye-drops-on-axial-length-and-refraction-in-myopic-children-compared-to-a-control-group-100628042",false,"NCT07456488","The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group","Inclusion Criteria:\n\n* Children aged 4-16 years\n* Both genders\n* Myopia of baseline SER of -1.00D or more\n* Astigmatism less than or equal to -2.50D\n* No medical history predisposing severe myopia (e.g., Marfan syndrome, Stickler syndrome, and retinopathy of prematurity), abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus, and spherophakia)\n* No history of other vision-threatening ocular diseases or previous intraocular surgery.\n* No current or previous use of atropine or pirenzipine, contact lenses or other forms of treatment that may affect myopia progression.\n\nExclusion Criteria:\n\n* Astigmatism ≥ 2.5 D\n* Anisometropia\\>1 D\n* Best corrected visual acuity \\\u003C 0.5 (6\u002F12)\n* Prior intraocular surgery\n* Allergy to atropine eye drops\n* Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome\n* History of cardiac or significant respiratory diseases\n* Lack of consent for participating in the study","ALL","4 Years","16 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","In this study, atropine 0.01% eye drops will be given to myopic children once at night daily for 6 months as compared to a control group to see the effect on axial length and refraction",[70],"Focus on Axial Length","2026-03-03",{"date":73,"type":74},"2026-03-06","ACTUAL",{"date":76,"type":74},"2025-07-13",{"date":78,"type":64},"2026-04-30",{"name":5,"class":6},1]